The multifunctional protein p11 amplifies serotonin receptor-mediated signaling ([@R1],[@R2]) and regulates gene transcription ([@R3],[@R4]). P11 levels are reduced in neurons of the frontal cortex, nucleus accumbens and hippocampus from depressed individuals and suicide victims ([@R1],[@R5]). Neuronal p11 levels are also reduced in animal models of depression ([@R1]), but are up-regulated by various antidepressant treatments, including selective serotonin reuptake inhibitors (SSRIs) ([@R1],[@R6]). P11 knockout (KO) mice show a depression-like phenotype and reduced behavioral improvements and neurogenesis in response to antidepressant regimens ([@R6],[@R7]). Conversely, overexpression of p11 in mice mimics the behavioural phenotype seen after antidepressant treatment ([@R1]). Here, we examined the possibility that p11 in white blood cells could serve as a biomarker of antidepressant response using the SSRI, citalopram.

After giving informed consent, 26 patients with MDD in a current major depressive episode were recruited at the National Institute of Mental Health (for details see [Supplementary information](#SD1){ref-type="supplementary-material"}). Their average (SD) age was 36.9±10.4 and there were 11 females and 15 males. The patients were screened and diagnosed using DSM-IV and SCID criteria. Severity of depression was assessed using the Montgomery--Åsberg Depression Rating Scale (MADRS) and the Quick Inventory of Depressive Symptomatology-C16 (QIDS). Subjects were given a daily dosage of citalopram, doses were increased over time (see [Supplementary information](#SD1){ref-type="supplementary-material"}), but were held constant for the week before blood was drawn. Subjects were evaluated on a weekly basis for eight weeks. Peripheral blood mononuclear cells (PBMCs) were prepared at baseline, and following two and eight weeks of citalopram treatment; 14 patients had all three sets of blood collected. A separate group of nine patients with MDD were recruited at UT Southwestern in Dallas and assessed using the Inventory of Depressive Symptomatology (IDS) (for details see [Supplementary information](#SD1){ref-type="supplementary-material"}). They were treated with citalopram and had blood collected at baseline, and following one and twelve weeks; 6 patients had all three sets of blood collected. The protocols were approved by local IRBs. The PBMC samples were coded at the NIMH and UT Southwestern, respectively. All subsequent analysis and quantifications of p11 were done blind at Karolinska Institutet. PBMCs were isolated and stored at −80°C in 90% FCS/10% DMSO. For analysis, PBMCs were thawed, washed in PBS, permeabilised and incubated for 30 min at +4°C with anti-human p11 (148; 2.5 µg/ml; BD Biosciences, Stockholm) or isotype control mouse IgG1 monoclonal antibodies. Bound antibody was detected by PE-conjugated anti-mouse antibody (Dako, Glostrup). To distinguish between NK cells, monocytes, and T cells, surface staining (CD3, CD14 and CD56; BD Biosciences) was performed after blocking of unbound anti-mouse antibody using 1% normal mouse serum (Sigma, Stockholm). After labeling, cells were subjected to flow cytometry analysis to detect p11 levels in gated populations of white blood cells ([Fig S1](#SD1){ref-type="supplementary-material"}). Analyses were done using FlowJo software (Tree Star Inc, Ashland). Statistical analyses used Pearson's correlation test and determined 95% confidence intervals (GraphPad Prism5, La Jolla).

Flow cytometry analysis of PBMCs showed that p11 was present in essentially all CD3−CD56+ NK cells ([Fig 1A](#F1){ref-type="fig"}), all CD14+ monocytes ([Fig 1B](#F1){ref-type="fig"}) and most CD3+ T cells ([Fig 1C](#F1){ref-type="fig"}), with monocytes having an order of magnitude higher levels. Clinical evaluations showed that most patients in the NIMH cohort responded to citalopram (see [Supplementary Information](#SD1){ref-type="supplementary-material"}). P11 was reduced in NK cells and monocytes after two weeks of citalopram and this reduction correlated with clinical improvements on MADRS ([Fig 1](#F1){ref-type="fig"}; r=0.61 (0.09--0.87) and r=0.58 (0.07--0.85); p\<0.05) and QIDS ([Fig S2](#SD1){ref-type="supplementary-material"}; r=0.60 (0.08--0.87) and r=0.61 (0.12--0.86); p\<0.05) as assessed after eight weeks of citalopram. Correlations were likewise found when comparing p11 reductions and clinical improvements after eight weeks of citalopram (data not shown). Similarly, p11 was reduced in NK cells and monocytes after one week of citalopram in patients recruited at UT Southwestern and this reduction correlated with clinical improvements on IDS ([Fig S3](#SD1){ref-type="supplementary-material"}; r=0.87 (0.22--0.98) and r=0.81 (0.01--0.98); p\<0.05) as assessed after twelve weeks of citalopram. Taken together, the data thus suggest that early reductions of p11 levels in NK cells and monocytes in response to citalopram predict the likelihood of a later antidepressive response. Baseline p11 levels did not correlate with baseline MADRS or citalopram-induced improvements on the MADRS ([Fig S4](#SD1){ref-type="supplementary-material"}).

Since animal studies have shown that antidepressants increase p11 in neurons in the brain ([@R4]), it appears paradoxical that a decrease in p11 in white blood cells should be associated with antidepressant response. Future studies will need to examine whether antidepressants regulate p11 in microglia, which, like monocytes, are derived from myeloid precursors. Future clinical studies, using citalopram and other antidepressants with larger sample sizes, need to be carried out. If such studies confirm the results of the present investigation, early analyses of p11 levels would guide clinicians in deciding whether treatment with a particular antidepressant should continue or whether it would be better to switch to another antidepressant therapy.
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![p11 in NK cells, monocytes, and T cells and its regulation by citalopram in depressed individuals\
Representative flow cytometry analysis of PBMCs with primary antibodies towards p11 (red lines) or IgG1 isotype control (grey lines) demonstrates specific p11 expression in essentially all (A) CD56+CD3− NK cells and all (B) CD14+monocytes and in most (C) CD3+ T cells. (D--F) Graphs showing median fluorescence intensity of p11 (percentage of baseline values) in (D) NK cells, (E) monocytes, and (F) T cells after two weeks of citalopram treatment and correlations to improvements in total MADRS score after eight weeks of citalopram treatment. Dots represent individual patients. Statistical analyses used Pearson's correlation test and determined 95% confidence intervals. Statistical significance was defined as P\<0.05.](nihms560316f1){#F1}
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